MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Total Assets 2011-2026 | OPK
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.2 B | 2.01 B | 2.17 B | 2.4 B | 2.47 B | 2.31 B | 2.45 B | 2.58 B | 2.77 B | 2.8 B | 1.27 B | 1.39 B | 290 M | 229 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.8 B | 229 M | 1.95 B |
Quarterly Total Assets OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.97 B | 2.13 B | 2.26 B | 1.98 B | 1.97 B | 2.06 B | 2.16 B | 2.17 B | 2.17 B | 2.22 B | - | 2.31 B | 2.4 B | 2.42 B | 2.42 B | 2.52 B | 2.47 B | 2.47 B | 2.47 B | 2.47 B | 2.31 B | 2.31 B | 2.31 B | 2.31 B | 2.45 B | 2.45 B | 2.45 B | 2.45 B | 2.59 B | 2.59 B | 2.59 B | 2.59 B | 2.77 B | 2.77 B | 2.77 B | 2.77 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 1.27 B | 1.27 B | 1.27 B | 1.27 B | 1.39 B | 1.39 B | 1.39 B | 1.39 B | 290 M | 290 M | 290 M | 290 M | 229 M | 229 M | 229 M | 229 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.8 B | 229 M | 1.95 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 2.85 | -3.72 % | $ 92.5 K |  USA |
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
10.7 B | $ 118.6 | 0.4 % | $ 36.1 B | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Celcuity
CELC
|
245 M | $ 107.62 | -0.63 % | $ 4.25 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 13.82 | -2.68 % | $ 418 M | USA |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
531 M | $ 27.55 | -1.59 % | $ 765 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 175.77 | -1.61 % | $ 8.71 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 108.44 | 0.16 % | $ 8.94 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.35 B | $ 635.29 | -0.22 % | $ 51.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 283.19 | -1.07 % | $ 23.6 B | USA |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 79.15 | 3.74 % | $ 5.34 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K |  Israel |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 315.61 | -0.56 % | $ 27.1 B |  Schweiz |
|
Biodesix
BDSX
|
97.2 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Myriad Genetics
MYGN
|
707 M | $ 5.26 | 4.89 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 9.53 | 0.26 % | $ 1.22 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
122 M | $ 13.37 | -3.47 % | $ 328 M | USA |
 |
Natera
NTRA
|
1.39 B | $ 206.39 | 3.11 % | $ 20.3 B | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.12 | -1.78 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 208.28 | -0.95 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 204.04 | -0.9 % | $ 145 B | USA |
 |
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | $ 103.38 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
811 M | $ 8.8 | 0.34 % | $ 551 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.3 | -4.19 % | $ 292 M | Israel |
 |
DexCom
DXCM
|
6.34 B | $ 73.0 | -1.06 % | $ 28.5 B | USA |
 |
PerkinElmer
PKI
|
12.2 B | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
12.3 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
18.1 M | $ 24.78 | 0.38 % | $ 32.2 M | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
220 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 24.01 | -4.59 % | $ 254 M | China |
 |
Illumina
ILMN
|
6.3 B | $ 129.9 | -2.25 % | $ 20.7 B | USA |
 |
Renalytix AI plc
RNLX
|
7.97 M | - | 5.66 % | $ 22.7 M | Britain |
 |
VolitionRx Limited
VNRX
|
9.4 M | $ 0.2 | -0.74 % | $ 19.2 M |  Singapore |